Pre-made Apitegromab benchmark antibody ( Whole mAb, anti-pro-GDF-8 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Apitegromab biosimilar, Whole Mab: Anti-pro-GDF-8 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Apitegromab (SRK 015) is an anti-promyostatin monoclonal antibody that is being developed by Scholar Rock, for the treatment of spinal muscular atrophy (SMA), muscle-wasting disorders and spinal cord injuries.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-030-1mg	1mg	3090
GMP-Bios-ab-030-10mg	10mg	Inquiry
GMP-Bios-ab-030-100mg	100mg	Inquiry
GMP-Bios-ab-030-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Apitegromab biosimilar, Whole Mab: Anti-pro-GDF-8 therapeutic antibody
INN Name	Apitegromab
Target	pro-GDF-8
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	6umx:HL:hl
Year Proposed	2020
Year Recommended	2021
Companies	Scholar Rock
Conditions Approved	na
Conditions Active	Spinal muscular atrophy;Muscular atrophy;Spinal cord injuries
Conditions Discontinued	na
Development Tech	na